Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
复制标题
DOI：
10.2217/fon.13.47
复制
发表时间：
2013-07
期刊：
影响因子：
--
通讯作者：
Bigner DD
中科院分区：
文献类型：
--
作者：
Chandramohan V;Mitchell DA;Johnson LA;Sampson JH;Bigner DD
通过手术、辅助放疗和化疗策略的进步，脑肿瘤患者的生存率得到了适度的改善。然而，这些传统的方法在永久控制这些侵袭性肿瘤方面并不成功，复发是相当常见的。因此，需要特异性靶向分子多样性脑肿瘤细胞群的新治疗方法。免疫系统识别改变的肿瘤细胞的能力，同时避免周围的正常细胞提供了一个巨大的优势，超过非特异性的传统治疗方案。因此，免疫疗法代表了一种有前途的方法，可以补充标准疗法消除残留的脑肿瘤细胞。这篇综述总结了目前正在测试的恶性脑肿瘤治疗的不同免疫方法。
Modest improvement in brain tumor patient survival has been achieved through advances in surgical, adjuvant radiation and chemotherapeutic strategies. However, these traditional approaches have been unsuccessful in permanently controlling these aggressive tumors, with recurrence being quite common. Hence, there is a need for novel therapeutic approaches that specifically target the molecularly diverse brain tumor cell population. The ability of the immune system to recognize altered tumor cells while avoiding surrounding normal cells offers an enormous advantage over the nonspecific nature of the conventional treatment schemes. Therefore, immunotherapy represents a promising approach that may supplement the standard therapies in eliminating the residual brain tumor cells. This review summarizes different immunotherapeutic approaches currently being tested for malignant brain tumor treatment.